	Applica
	Filing D
INFORMATION DISCLOSURE	First Na

STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10588740				
· ····•		2006-08-04				
		Hermida Santos				
		1645				
Attorney Docket Number		020884-000011				

					U.S.F	PATENTS			Remove	
Examiner No Patent Number Kind Code1 Issue Date Name of Patentee or Applicant of cited Document				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1	6037450	A	2000-03	3-14	Esmon et al.				
	2 6617145 B2 2003-09-09 Boone et al.									
If you wish	n to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
	U.S.PATENT APPLICATION PUBLICATIONS Remove									
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva	s,Columns,Lines wher ant Passages or Rele es Appear	
	1									
If you wish	n to a	l dd additional U.S. Publi	shed Ap	plication	citation	ln information p	olease click the Ad-	L d buttor	n. Add	
•				FOREIG	3N PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Applicant of cited		eor	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5				
	1	0600088	EP		A1	1994-06-08	Koike et al.			
If you wish	n to ac	dd additional Foreign Pa	atent Do	cument	L citation	information p	Lease click the Add	button	Add	
•						RATURE DO			Remove	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

/Bao-Thuy Nguyen/

09/01/2009

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

pplication Number		10588740
ling Date		2006-08-04
rst Named Inventor	Jose I	Hermida Santos
rt Unit		1645
xaminer Name		
torney Docket Number	er	020884-000011

				Attorney Docket Numb	er	020884-000011					
Examiner Initials*	Cite No	(boo	nclude name of the author (in CAPTAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), bublisher, city and/or country where published.								
	1	Prote	STING, et al., "Antiphospholipid Antibodies Directed Against a Combination of Phospholipids with Prothrombin, tein C, or Protein S: An Explanation of Their Pathogenic Mechanism?" Blood. Mayo, Vol. 81, No. 10, (1993), pp.								
	2		GU, et al., "Disruption of the Endothelial Cell Protein C Receptor Gene in Mice Causes Placental Thrombosis and Early Embryonic Lethality," The Journal of Biological Chemistry, Vol. 277, No. 45, (2002), pp. 43335-43343.								
If you wis	h to a	dd add	ditional non-patent literatur	e document citation infor	mation	n please click the Add b	outton Add				
				EXAMINER SIGNAT	URE						
Examiner	Signa	ature	/Bao-Thuy Nguyen/			Date Considered	09/01/2009				
			reference considered, who								

F

Α

F

catation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 
2 Enter office that issued the document, by the two-letter code (WIPO).

Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

\*\*Ikind document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10588740
Filing Date		2006-08-04
First Named Inventor Jose		Hermida Santos
Art Unit		1645
Examiner Name		
Attorney Docket Number		020884-000011

#### CERTIFICATION STATEMENT

	11 1
	That each item of information contained in the information disclosure statement was first cited in any communication
$\neg$	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

information disclosure statement. See 37 CFR 1.97(e)(1).

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Non

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Tristan A. Fulerer/	Date (YYYY-MM-DD)	2006-11-20
Name/Print	Tristan A. Fuierer	Registration Number	52,926

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22314-156.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of hext, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
  (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
  Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement necotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.